Clinical Trial

Cardiac Sarcoidosis Randomized Trial

Study acronym: CHASM-CS-RCT
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Prospective randomized controlled trial comparing low dose Prednisone(or Prednisolone)/Methotrexate combination to standard dose Prednisone(or Prednisolone) in patients diagnosed with acute active clinically manifest cardiac sarcoidosis and not yet treated. The Investigators hypothesize that low dose Prednisone(or Prednisolone)/Methotrexate combination will be as effective as standard dose Prednisone(or Prednisolone), and result in significantly better quality of life and less toxicity than standard dose Prednisone(or Prednisolone).
Protocol Amendment History 1 change
notable Enrollment reduced: 194 -> 160 participants 2026-07-11
Trial Details
NCT Number NCT03593759
Lead Sponsor Ottawa Heart Institute Research Corporation
Collaborators: Canadian Institutes of Health Research (CIHR)
Conditions Cardiac Sarcoidosis, Sarcoidosis
Enrollment 160 participants
Start Date 2019-01-15
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-10